Milne R - Search Results

1

MAP kinase-interacting kinases--emerging targets against cancer.

Diab S, Kumarasiri M, Yu M, Teo T, Proud C, Milne R, Wang S. Diab S, et al. Among authors: milne r. Chem Biol. 2014 Apr 24;21(4):441-452. doi: 10.1016/j.chembiol.2014.01.011. Epub 2014 Mar 6. Chem Biol. 2014. PMID: 24613018 Review.

2

Unveiling new chemical scaffolds as Mnk inhibitors.

Diab S, Li P, Basnet SK, Lu J, Yu M, Albrecht H, Milne RW, Wang S. Diab S, et al. Future Med Chem. 2016;8(3):271-85. doi: 10.4155/fmc.15.190. Epub 2016 Feb 24. Future Med Chem. 2016. PMID: 26910782

3

Targeting CDK9: a promising therapeutic opportunity in prostate cancer.

Rahaman MH, Kumarasiri M, Mekonnen LB, Yu M, Diab S, Albrecht H, Milne RW, Wang S. Rahaman MH, et al. Endocr Relat Cancer. 2016 Dec;23(12):T211-T226. doi: 10.1530/ERC-16-0299. Epub 2016 Aug 31. Endocr Relat Cancer. 2016. PMID: 27582311 Review.

4

Dual Inhibition of Mnk2 and FLT3 for potential treatment of acute myeloid leukaemia.

Diab S, Abdelaziz AM, Li P, Teo T, Basnet SKC, Noll B, Rahaman MH, Lu J, Hou J, Yu M, Le BT, Albrecht H, Milne RW, Wang S. Diab S, et al. Eur J Med Chem. 2017 Oct 20;139:762-772. doi: 10.1016/j.ejmech.2017.08.006. Epub 2017 Aug 3. Eur J Med Chem. 2017. PMID: 28863357

5

Discovery of N-Phenyl-4-(1H-pyrrol-3-yl)pyrimidin-2-amine Derivatives as Potent Mnk2 Inhibitors: Design, Synthesis, SAR Analysis, and Evaluation of in vitro Anti-leukaemic Activity.

Abdelaziz AM, Diab S, Islam S, Basnet SKC, Noll B, Li P, Mekonnen LB, Lu J, Albrecht H, Milne RW, Gerber C, Yu M, Wang S. Abdelaziz AM, et al. Med Chem. 2019;15(6):602-623. doi: 10.2174/1573406415666181219111511. Med Chem. 2019. PMID: 30569866

6

Discovery of 5-(2-(phenylamino)pyrimidin-4-yl)thiazol-2(3H)-one derivatives as potent Mnk2 inhibitors: synthesis, SAR analysis and biological evaluation.

Diab S, Teo T, Kumarasiri M, Li P, Yu M, Lam F, Basnet SK, Sykes MJ, Albrecht H, Milne R, Wang S. Diab S, et al. Among authors: milne r. ChemMedChem. 2014 May;9(5):962-72. doi: 10.1002/cmdc.201300552. Epub 2014 Feb 12. ChemMedChem. 2014. PMID: 24677692

7

Targeting Pim kinases for cancer treatment: opportunities and challenges.

Le BT, Kumarasiri M, Adams JR, Yu M, Milne R, Sykes MJ, Wang S. Le BT, et al. Among authors: milne r. Future Med Chem. 2015;7(1):35-53. doi: 10.4155/fmc.14.145. Future Med Chem. 2015. PMID: 25582332 Review.

8

Highly Potent, Selective, and Orally Bioavailable 4-Thiazol-N-(pyridin-2-yl)pyrimidin-2-amine Cyclin-Dependent Kinases 4 and 6 Inhibitors as Anticancer Drug Candidates: Design, Synthesis, and Evaluation.

Tadesse S, Yu M, Mekonnen LB, Lam F, Islam S, Tomusange K, Rahaman MH, Noll B, Basnet SK, Teo T, Albrecht H, Milne R, Wang S. Tadesse S, et al. Among authors: milne r. J Med Chem. 2017 Mar 9;60(5):1892-1915. doi: 10.1021/acs.jmedchem.6b01670. Epub 2017 Feb 16. J Med Chem. 2017. PMID: 28156111 Free article.

9

Discovery and pharmacological characterization of a novel series of highly selective inhibitors of cyclin-dependent kinases 4 and 6 as anticancer agents.

Tadesse S, Bantie L, Tomusange K, Yu M, Islam S, Bykovska N, Noll B, Zhu G, Li P, Lam F, Kumarasiri M, Milne R, Wang S. Tadesse S, et al. Among authors: milne r. Br J Pharmacol. 2018 Jun;175(12):2399-2413. doi: 10.1111/bph.13974. Epub 2018 May 8. Br J Pharmacol. 2018. PMID: 28800675 Free PMC article.

10

CDK5 in oncology: recent advances and future prospects.

Lenjisa JL, Tadesse S, Khair NZ, Kumarasiri M, Yu M, Albrecht H, Milne R, Wang S. Lenjisa JL, et al. Among authors: milne r. Future Med Chem. 2017 Oct;9(16):1939-1962. doi: 10.4155/fmc-2017-0097. Epub 2017 Oct 27. Future Med Chem. 2017. PMID: 29076761 Review.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

1,412 results

Search Page